vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
TSS, Inc. is the larger business by last-quarter revenue ($60.9M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). TSS, Inc. runs the higher net margin — 20.0% vs -83.0%, a 102.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 21.8%). Over the past eight quarters, TSS, Inc.'s revenue compounded faster (95.8% CAGR vs 48.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RYTM vs TSSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $60.9M |
| Net Profit | $-47.5M | $12.2M |
| Gross Margin | 91.6% | 17.6% |
| Operating Margin | -82.2% | 1.5% |
| Net Margin | -83.0% | 20.0% |
| Revenue YoY | 36.9% | 21.8% |
| Net Profit YoY | -9.6% | 535.7% |
| EPS (diluted) | $-0.73 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $60.9M | ||
| Q3 25 | $51.3M | $41.9M | ||
| Q2 25 | $48.5M | $44.0M | ||
| Q1 25 | $32.7M | $99.0M | ||
| Q4 24 | $41.8M | $50.0M | ||
| Q3 24 | $33.3M | $70.1M | ||
| Q2 24 | $29.1M | $12.2M | ||
| Q1 24 | $26.0M | $15.9M |
| Q4 25 | $-47.5M | $12.2M | ||
| Q3 25 | $-52.9M | $-1.5M | ||
| Q2 25 | $-46.6M | $1.5M | ||
| Q1 25 | $-49.5M | $3.0M | ||
| Q4 24 | $-43.3M | $1.9M | ||
| Q3 24 | $-43.6M | $2.6M | ||
| Q2 24 | $-32.3M | $1.4M | ||
| Q1 24 | $-141.4M | $15.0K |
| Q4 25 | 91.6% | 17.6% | ||
| Q3 25 | 89.3% | 11.1% | ||
| Q2 25 | 88.6% | 17.8% | ||
| Q1 25 | 88.8% | 9.3% | ||
| Q4 24 | 90.9% | 14.4% | ||
| Q3 24 | 88.5% | 11.3% | ||
| Q2 24 | 89.9% | 37.3% | ||
| Q1 24 | 89.2% | 17.1% |
| Q4 25 | -82.2% | 1.5% | ||
| Q3 25 | -102.6% | -2.2% | ||
| Q2 25 | -93.4% | 5.1% | ||
| Q1 25 | -143.7% | 4.2% | ||
| Q4 24 | -98.6% | 0.0% | ||
| Q3 24 | -132.0% | 5.4% | ||
| Q2 24 | -139.2% | 14.0% | ||
| Q1 24 | -538.7% | 1.6% |
| Q4 25 | -83.0% | 20.0% | ||
| Q3 25 | -103.1% | -3.6% | ||
| Q2 25 | -96.1% | 3.4% | ||
| Q1 25 | -151.4% | 3.0% | ||
| Q4 24 | -103.6% | 3.8% | ||
| Q3 24 | -131.2% | 3.8% | ||
| Q2 24 | -110.9% | 11.5% | ||
| Q1 24 | -544.4% | 0.1% |
| Q4 25 | $-0.73 | $0.44 | ||
| Q3 25 | $-0.82 | $-0.06 | ||
| Q2 25 | $-0.75 | $0.06 | ||
| Q1 25 | $-0.81 | $0.12 | ||
| Q4 24 | $-0.71 | $0.08 | ||
| Q3 24 | $-0.73 | $0.10 | ||
| Q2 24 | $-0.55 | $0.06 | ||
| Q1 24 | $-2.35 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $76.6M |
| Total Assets | $480.2M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $85.5M | ||
| Q3 25 | $416.1M | $70.7M | ||
| Q2 25 | $291.0M | — | ||
| Q1 25 | $314.5M | — | ||
| Q4 24 | $320.6M | $23.2M | ||
| Q3 24 | $298.4M | $46.4M | ||
| Q2 24 | $319.1M | $8.3M | ||
| Q1 24 | $201.2M | $14.4M |
| Q4 25 | $139.1M | $76.6M | ||
| Q3 25 | $148.8M | $63.4M | ||
| Q2 25 | $-11.9M | $9.5M | ||
| Q1 25 | $18.9M | $9.4M | ||
| Q4 24 | $21.7M | $7.1M | ||
| Q3 24 | $11.2M | $7.7M | ||
| Q2 24 | $39.3M | $5.2M | ||
| Q1 24 | $61.6M | $3.7M |
| Q4 25 | $480.2M | $184.9M | ||
| Q3 25 | $506.9M | $165.4M | ||
| Q2 25 | $372.7M | $139.5M | ||
| Q1 25 | $386.7M | $113.5M | ||
| Q4 24 | $392.3M | $96.6M | ||
| Q3 24 | $363.6M | $67.3M | ||
| Q2 24 | $381.8M | $28.9M | ||
| Q1 24 | $258.7M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $16.3M |
| Free Cash FlowOCF − Capex | — | $15.8M |
| FCF MarginFCF / Revenue | — | 25.9% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $16.3M | ||
| Q3 25 | $-26.6M | $-18.4M | ||
| Q2 25 | $-23.3M | $16.3M | ||
| Q1 25 | $-40.4M | $20.6M | ||
| Q4 24 | $-18.8M | $-21.6M | ||
| Q3 24 | $-25.2M | $38.6M | ||
| Q2 24 | $-29.1M | $-4.3M | ||
| Q1 24 | $-40.7M | $2.6M |
| Q4 25 | — | $15.8M | ||
| Q3 25 | — | $-24.9M | ||
| Q2 25 | — | $5.4M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | — | $-28.4M | ||
| Q3 24 | — | $38.6M | ||
| Q2 24 | — | $-6.0M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | 25.9% | ||
| Q3 25 | — | -59.3% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | -56.7% | ||
| Q3 24 | — | 55.1% | ||
| Q2 24 | — | -49.4% | ||
| Q1 24 | — | 16.4% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 13.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 11.02× | ||
| Q1 25 | — | 6.93× | ||
| Q4 24 | — | -11.32× | ||
| Q3 24 | — | 14.60× | ||
| Q2 24 | — | -3.09× | ||
| Q1 24 | — | 176.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
